Loading…

Evolus, Inc.EOLSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum neutral 46
Mkt cap
$468M
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$7.64M
20-day average traded
Fwd P/E
28.5×
forward earnings
ROIC−WACC
-25.2 pp
WACC 10.3%
Hurdle
n/a
no reverse DCF
Next earnings
111 days
9 Mar 2027
Close · USD$7.07
1D+5.7%
1W-4.7%
1M-4.1%
3M-15.3%
6M+7.3%
YTD+6.3%
1Y+1.7%
ATR %5.9%
Beta1.31
52w lowhigh24.1% off high

What Evolus does

Employees: 334

Evolus at a glance

Size Evolus (EOLS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $468M, the 2718th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.07 on 18 Nov 2026.

Performance Over six months the shares gained 7.3%, against -9.3% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue grew 13.9% over the last twelve months (peer median +12.5%); the operating margin is -5.0% (peer median 7.6%).

Valuation It trades at 28.5× forward earnings against a peer median of 24.0× (2nd most expensive of 5).

Capital Return on invested capital runs 25.2 points below its cost of capital (10.3% WACC).

Short interest Short interest is 9.1% of the free float (30 Oct 2026).

Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026EOLS 110Peer median 89
Six months, rebased to 100: Evolus against the median of its 20 peers (local-currency closes).

Evolus financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$325M$297M$266M$202M$149M
Revenue growth—+12%+32%+36%—
Gross profit$210M$193M$180M$135M$89.0M
EBITDA-$5.28M-$28.9M-$21.2M-$30.2M-$55.1M
Net income-$31.1M-$51.6M-$50.4M-$61.7M-$74.4M
Free cash flow-$4.91M-$45.7M-$19.5M-$34.5M-$86.5M
Capital expenditure$6.17M$8.45M$4.82M$1.63M$2.94M
Total debt$166M$155M$130M$127M$74.4M

Quarterly statements and history in the cockpit →

Evolus competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%0023706620CAPRKPL0026933012013705AQSTSMSPHARMAASMBHNSARGNX688373GUFICBIO003020300584301277EOLS6-month return →1-month return →
Up and to the right = strong over both horizons. Evolus is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%20×30×40×6620SMSPHARMA003020603566EOLSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Evolus is the large dot.

Evolus competitors and peer comparison

How Evolus compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Evolus against its 20 peers (data as of 18 Nov 2026)
MeasureEOLSPeer medianRank in peer set
1-month return-4.1%-2.1%10th lowest of 21
6-month return+7.3%-9.3%7th highest of 20
Distance from 52-week high-24.1%-39.2%6th highest of 21
Revenue growth (TTM)+13.9%+12.5%9th highest of 20
Operating margin-5.0%7.6%9th lowest of 19
Forward P/E28.5×24.0×2nd most expensive of 5
ROIC minus cost of capital-25.2 pp-3.3 pp4th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Evolus EOLSUnited States$468M+7%+14%-5%28.5×n/an/a
Zhejiang Yatai Pharmaceutical 002370.SZChina$468M-32%-4%-11%n/an/an/a
Handa Pharmaceuticals 6620.TWOTaiwan$469M+45%-16%30%24.9×24.8%+126.7%
Capricor Therapeutics CAPRUnited States$467M-70%-100%n/an/an/an/a
Kwality Pharmaceuticals KPL.NSIndia$467M+110%+48%22%n/an/an/a
Hainan Shuangcheng Pharmaceuticals 002693.SZChina$465M-28%+40%13%n/a44.1%+1.0%
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%n/an/an/a
BlossomHill Therapeutics BLSMUnited States$464Mn/an/an/an/an/an/a
YungShin Global 3705.TWTaiwan$472M+5%-5%15%n/a-3.8%+0.7%
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%n/an/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%42.2×n/an/a
Assembly Biosciences ASMBUnited States$458M-15%+80%-32%n/an/an/a
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%n/an/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%n/a-4.7%+105.3%
REGENXBIO RGNXUnited States$480M+22%-5%-120%n/an/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%n/an/an/a
Gufic Biosciences GUFICBIO.NSIndia$452M+48%+17%14%n/an/an/a
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%18.2×n/an/a
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%n/a3.3%-1.1%
Pulike Biological Engineering 603566.SSChina$449M-21%-9%5%23.2×4.5%+3.3%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%n/a8.9%+9.1%

Questions

Which companies are Evolus's closest peers?
The cockpit's peer set: Zhejiang Yatai Pharmaceutical (002370.SZ), Handa Pharmaceuticals (6620.TWO), Capricor Therapeutics (CAPR), Kwality Pharmaceuticals (KPL.NS), Hainan Shuangcheng Pharmaceuticals (002693.SZ), ChengDa PharmaCeuticals (301201.SZ), BlossomHill Therapeutics (BLSM), YungShin Global (3705.TW).
Is Evolus expensive compared with its peers?
On forward p/e it trades at 28.5× against a peer median of 24.0×, 2nd most expensive of 5 in its peer set.
How has Evolus stock performed?
Over six months to 18 Nov 2026 the shares returned +7.3% against -9.3% for the median peer; over one year +1.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.